INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS

Pomerantz LLP is investigating potential securities fraud claims against Emergent BioSolutions following the company's August 5, 2026 earnings report. Emergent reported a $191.3 million non-cash impairment charge on its NARCAN asset group, resulting in a $180.2 million net loss, and cut full-year revenue guidance by 10.8%. The company attributed the decline to increased competitive intensity. Emergent's stock price fell 29.58% to $5.31 per share on August 6, 2026.